Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission-critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a company that places a high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, they strive to meet this challenge. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.David R. Walt, Satnam Alag, Larry Bock, and John Stuelpnagel co-founded Illumina in San Diego, California in 1998.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 4, 2023 | Post-IPO Debt | $750M | 1 | Bank of America | — | Detail |
Jan 10, 2000 | Series Unknown | $28M | 1 | — | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Sep 1, 2021
SomaLogic
|
Post-IPO Equity | $375M | Biotechnology | — |
Mar 1, 2018
Helix
|
Series B | $200M | Big Data | — |
Aug 15, 2015
Helix
|
Series A | $100M | Big Data | Yes |
Jun 9, 2015
Twist Bioscience
|
Series C | $37M | Biotechnology | Yes |
Apr 26, 2011
Oxford Nanopore Technologies
|
Series Unknown | £25M | Biopharma | — |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Bank of America | Yes | Post-IPO Debt |
ARCH Venture Partners | — | Series Unknown |